Guardian Pharmacy Services, Inc.(GRDN)Earnings, Financials & Key RatiosGuardian Pharmacy Services, Inc. (GRDN) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company has successfully de-risked its capital structure to a 0.16 debt-to-equity ratio, the current 54.24 P/E multiple appears difficult to justify given the persistent volatility in operating margins and inconsistent free cash flow generation.
Guardian Pharmacy Services, Inc. (GRDN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Guardian Pharmacy Services, Inc. (GRDN) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.29vs $0.24+20.8% | $337Mvs $330M+2.0% |
| Q2 2026 | Mar 11, 2026 | $0.37vs $0.27+37.0% | $398Mvs $390M+1.9% |
| Q4 2025 | Nov 10, 2025 | $0.25vs $0.24+4.2% | $377Mvs $390M-3.2% |
| Q3 2025 | Aug 11, 2025 | $0.23vs $0.22+4.5% | $344Mvs $344M+0.1% |
Recent stock market news and headlines for Guardian Pharmacy Services, Inc. (GRDN)
Guardian Pharmacy (GRDN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) today announced that Kendall Forbes, who has served as Executive Vice President of Sales & Operations since 2004, has decided to retire, effective as of July 1, 2026. Upon Mr. Forbes's retirement, David Morris, currently Executive Vice President and Chief Financial Officer of Guardian will assume the role of Chief Operating Officer. In connection with Mr. Morris' new role, Will Mudd, Senior Vice President, Finance, has b.
Key metrics vs top competitors for Guardian Pharmacy Services, Inc. (GRDN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $41.38 | $2.62B | 53.05 | 17.93% | 3.4% | 26.76% | — | |
| $45.24 | $2.06B | 1021.22 | 6.53% | 1.67% | 1.64% | — | |
| $28.26 | $2.34B | 128.45 | -10.86% | -2.42% | -1.59% | — | |
| $102.08 | $130.25B | 73.44 | 7.85% | 0.72% | 3.86% | — | |
| $13.20 | $426.79M | -4.51 | -21.56% | -9.84% | -27.1% | — | |
| $784.23 | $94.27B | 20.43 | 12.36% | 1.18% | — | — |
Guardian Pharmacy Services, Inc. (GRDN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Guardian Pharmacy Services, Inc. (GRDN) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 7, 2026·SEC
May 6, 2026·SEC
Mar 23, 2026·SEC
Get notified when GRDN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Guardian Pharmacy Services, Inc. (GRDN) stock FAQ — growth, dividends, profitability & financials explained
Guardian Pharmacy Services, Inc. (GRDN) reported $1.46B in revenue for fiscal year 2025. This represents a 143% increase from $600.4M in 2018.
Guardian Pharmacy Services, Inc. (GRDN) grew revenue by 17.9% over the past year. This is strong growth.
Yes, Guardian Pharmacy Services, Inc. (GRDN) is profitable, generating $53.1M in net income for fiscal year 2025 (3.4% net margin).
Guardian Pharmacy Services, Inc. (GRDN) has a return on equity (ROE) of 26.8%. This is excellent, indicating efficient use of shareholder capital.
Guardian Pharmacy Services, Inc. (GRDN) generated $70.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
